Navigation Links
Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program
Date:12/10/2009

EMERYVILLE, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host an Analyst Briefing on December 17, 2009 at 8:30 a.m. ET.

The briefing, hosted by Onyx management, will provide an overview of its development program and feature presentations on multiple tumor types by external clinical investigators and members of management.

The live webcast, to begin at 8:30 a.m. ET, will be available on the Onyx website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

A replay of the webcast will be available on the Onyx website through December 31, 2009.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors, and ONX 0801, a targeted alpha-folate inhibitor, currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

SOURCE Onyx Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
2. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010
3. Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution
4. Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lees Pharmaceuticals
5. BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors
6. ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
7. Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis
8. Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
10. Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals Universal Flu Vaccine
11. Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... International plc (NASDAQ: ENDP ) today announced that ... U.S. mesh product liability claims and that it is ... claims at reasonable values. Under the agreements, Endo will ... 2017 and continuing through the fourth quarter of 2019. ... Company intends to increase its mesh product liability accrual ...
(Date:8/2/2017)... 2, 2017 Fenita J. Caldwell ... a Pinnacle Lifetime Professional in the Field of ... at Turing Pharmaceuticals, AG. Her skills and areas ... building.                ... years of experience as a highly successful sales ...
(Date:8/1/2017)... --  CerSci Therapeutics , a non-opioid drug development firm ... received notice from the National Institute on Drug Abuse ... it has been awarded a Direct-to-Phase II Small Business ... with an additional $1,000,000 to follow in 2018. These ... their lead non-opioid drug candidate CT-044 to the Food ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 ... bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner for people ... such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage ... up its marketing efforts with its product now available through Jet.com. , After ... public. The effervescent powdered drink is designed to quickly detox the body thereby avoiding ...
(Date:8/18/2017)... ... 2017 , ... 800response, the leading provider of dynamic call-to-action ... launch of a redesigned corporate website, 800response.com . , Key features ... an enhanced search directory for businesses and advertising agencies to use to ...
(Date:8/18/2017)... ... ... “Dangerous Inheritance”: a mystery about saving the family farm. “Dangerous Inheritance” ... where she was raised on a farm. As Diane wrote this story, she ... friendships and mantra of ‘neighbors helping neighbors’ have always been a large part of ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Beyond Our Imaginations: The Infinite God”: shows the ... Infinite God” is the creation of published author, Mark Lawrence, born in Michigan, the ... “The problem with becoming a greater man of God is that I have to ...
Breaking Medicine News(10 mins):